A Novel Nutritional Immune Risk Score Model for Long-Term Prognosis in Colorectal Cancer Using Clustering and Principal Component Analysis

Why It Matters

NIRS provides a simple, blood‑based stratification tool that can guide postoperative monitoring and nutritional interventions, potentially improving survival in colorectal cancer. Integrating immune‑nutritional metrics fills a prognostic gap left by traditional staging systems.

Key Takeaways

• NIRS uses PNI, CEA, CA19-9, CA72-4.
• Cutoff 21.34 separates low- and high-risk CRC patients.
• High-risk group faces 1.72× mortality risk.
• PNI inversely correlates with tumor size across outcomes.

Pulse Analysis

Colorectal cancer survival varies widely even among patients with identical tumor stages, a discrepancy increasingly linked to patients’ nutritional and immune health. Malnutrition dampens immune surveillance, amplifies inflammation, and can accelerate tumor growth, yet most prognostic tools ignore these dimensions. Recognizing this gap, researchers at a major Chinese cancer center designed a Nutritional Immune Risk Score (NIRS) to blend readily available blood‑based nutritional indices with classic tumor markers, aiming to sharpen long‑term risk prediction for patients undergoing curative resection.

The investigators retrospectively analyzed 892 patients who had surgery in 2017 and were followed through 2023. Unsupervised machine‑learning grouped the cohort using k‑means clustering, while principal component analysis distilled the most informative features. Four variables survived the selection process—prognostic nutritional index (PNI), carcinoembryonic antigen (CEA), carbohydrate antigen 19‑9 (CA19‑9) and carbohydrate antigen 72‑4 (CA72‑4)—and were combined into the equation NIRS = 0.572 × PNI – 0.101 × CEA – 0.412 × CA19‑9 – 0.028 × CA72‑4. An optimal cutoff of 21.34 split patients into low‑ and high‑risk groups; the latter exhibited a 1.72‑fold higher hazard of death (p < 0.001).

The NIRS model offers clinicians a low‑cost, blood‑based tool to refine postoperative surveillance and to flag patients who may benefit from aggressive nutritional support. The inverse relationship between PNI and maximum tumor diameter suggests that preserving nutritional status could blunt tumor expansion, especially when PNI falls below 50. By integrating immune‑nutritional metrics with conventional tumor markers, the score bridges a long‑standing gap in colorectal cancer risk stratification, paving the way for personalized care pathways and prospective trials that test whether targeted diet or immunonutrition can improve survival outcomes.